HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Stern, A. Articles by Barrett-Connor, E. Search for Related Content PubMed PubMed Citation Articles by Stern, A. Articles by Barrett-Connor, E.

The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor B legend with bone mineral density in older adults: the Rancho Bernardo Study

Department of Family and Preventive Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0607, USA

(Correspondence should be addressed to G A Laughlin; Email: glaughlin{at}ucsd.edu)

Objective: The role of osteoprotegerin (OPG) and its receptor activator of nuclear factor B legend (RANKL) in the regulation of bone in humans remain unclear. We examined the sex-specific associations of serum OPG, RANKL, and their ratio with bone mineral density (BMD) in older adults.

Design: Participants were 681 community-dwelling adults, ages 45–90 years, who had serum OPG and RANKL measured and bone density scans in 1988–1991, with follow-up scans 5 and/or 10 years later.

Methods: Analyses were sex-specific; women using and not using estrogen were evaluated separately. Cross-sectional analyses used multivariable regression models; longitudinal analyses used repeated measures mixed effects models.

Results: In cross-sectional analyses, age- and weight-adjusted serum OPG levels were significantly positively associated with BMD at the lumbar spine in men, and at the femoral neck, total hip, and lumbar spine in women using estrogen, but not in non-users of estrogen. RANKL concentrations were significantly and inversely associated with BMD in men only, and at the total hip. Neither OPG nor RANKL was significantly associated with bone loss. Results for the RANKL/OPG ratio were the same as those for RANKL alone.

Conclusions: These results suggest a modulatory effect of both endogenous and exogenous sex hormones on the biologic interaction of OPG, RANKL, and bone.

This article has been cited by other articles:

				E. J. Samelson, K. E. Broe, S. Demissie, T. J. Beck, D. Karasik, S. Kathiresan, and D. P. Kiel Increased Plasma Osteoprotegerin Concentrations Are Associated with Indices of Bone Strength of the Hip J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1789 - 1795. [Abstract] [Full Text] [PDF]

				L. N. Bakhireva, G. A. Laughlin, R. Bettencourt, and E. Barrett-Connor Does Osteoprotegerin or Receptor Activator of Nuclear Factor-{kappa}B Ligand Mediate the Association between Bone and Coronary Artery Calcification? J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 2009 - 2012. [Abstract] [Full Text] [PDF]